FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More
Say and pronounce FDA Approvals In on SuperTTS.com Make Your Own Text-To-Speech Words Instantly
Info
Email Video to Friends
Receive Emails for Similar Videos
Repeat and Loop Video
Link to Video
Create Short URL Publish Text About This Video
Share on Facebook, Twitter, and more
See Recommended Videos For You
Description
Gina Columbus reports on FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, a new drug application in prostate cancer, results from 2 late-stage prostate cancer trials, and encouraging findings in a chronic lymphocytic leukemia study.Tags
cancer oncologyShare:
Copied!
Related
FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More 
FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation 
FDA Approvals in ALL and Breast Cancer, Priority Reviews in CML and Follicular Lymphoma, and More 
FDA Approvals in Hematologic Malignancies, sBLA Accepted in Multiple Myeloma, and More 
FDA Approvals in MSI-High Cancers, Priority Reviews in Gastric Cancer and FL, and More 
FDA Approval in Lung Cancer, Promising Findings in Hodgkin Lymphoma, and More 
Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More 
FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More 
FDA Approvals in ALL, Ovarian Cancer, Priority Review in CTCL, and sNDA Submitted in RCC 
FDA Approvals in Breast Cancer and NSCLC, NDA Accepted in HCC, and More 
FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More 
FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More 
FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More 
Three FDA Approvals, NCI Director Resigns, and More 
Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma 
FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More 
'Our Cancer Drug Is For Rich Westerners, Not Poor Indians' 
FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights 
FDA Approvals in Breast Cancer and Hodgkin Lymphoma, 2017 SGO Highlights, and More 
Clinical Experience: CDK4/6 Inhibitors in Breast Cancer 
Blood Cancer Awareness: Follicular Lymphoma patent shares her story 
FDA Approvals in Ovarian Cancer and Merkel Cell Carcinoma 
FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC 
FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC 
FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More 
Dr. Nastoupil on RPembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma 
Dr. Hamlin on Early Study of Ibrutinib/Buparlisib in MCL, FL, and DLBCL 
Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma 
Review on 2016 FDA Approvals, Halt on AML Trials, and More 
Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL 
FDA Approvals in NSCLC, Bladder Cancer, and Breast Cancer, and Death in CAR T-cell Therapy Trial 
Treatment of Follicular Lymphoma 
Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma 
Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma 
Rare Form Of Cancer Linked To Breast Implants 
FDA Approvals for Daratumumab and Osimertinib, Regulatory Advances in RCC and CLL, and More 
Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL 
FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More 
Addressing Unmet Needs in Salvage Therapy for FL 
FDA Approves MM-398, T-VEC, and Trabectedin, New Pembrolizumab Data, and More 
The impact of the FDA's approval of the first 'biosimilar' drug 
Dr. Leonard on Ibrutinib Combined With Chemotherapy in Follicular Lymphoma 
FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More 
Follicular Lymphoma: Diagnosis and Staging 
FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year 
Breast Implants Can Cause Rare Cancer, FDA Says 
Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL 
Managing Follicular Lymphoma 
Triggers to Initiate Therapy for Follicular Lymphoma 
Key Considerations for Treating Recurrent Ovarian Cancer 
Risk Stratifying Patients With Follicular Lymphoma 
The Evolving Landscape of Salvage Therapy for FL 
FDA Approval in Breast Cancer, Breakthrough Designations in AML and Bladder Cancer, and More 
Sandra Allen-Bard on Advocating for Patients with Leukemia and Lymphoma 
The death rate of prostate cancer is quite high here. 
Combination Therapy’s Role in Follicular Lymphoma 
Follicular Lymphoma; Triggers to Initiate Therapy 
21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC 
Stem Cell Transplantation in Follicular Lymphoma 
The FDA Approval of Atezolizumab in Bladder Cancer 
Novel Therapies in FL: Benefits and Challenges 
Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More 
The Future of Treatment in Follicular Lymphoma 
Biologic Drugs and Biosimilars 
Novartis Metastatic Breast Cancer Treatment 
FDA Approval of Durvalumab for Bladder Cancer 
FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights 
Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma 
Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma 
Non-Hodgkin’s Lymphoma: Exploring Subtypes 
FDA Approval of Brigatinib for ALK+ NSCLC 
FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More 
Systemic Treatment for Newly Diagnosed FL 
What's next in fighting cancer with polio virus? 
Hereditary Prostate Cancer Test Popular Today
